A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial.

Eur Heart J · 2019 · PMC6823615 · PMID 30993313

Europe PMC DOI

hedged sentence

0.0050

closest p · 0.1× alpha

0.0050

boldest claim

The sentences

highly significantP = 0.005actually significant

The treatment effect on LVM was greater when analysed using the per-protocol population with a highly significant reduction in LVM (change in LVM: metformin group −7.53 ± 4.66 g vs. placebo group −3.13 ± 6.36 g; P = 0.005).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.